DAURISMO Film-coated tablet Ref.[10664] Active ingredients: Glasdegib

Source: European Medicines Agency (EU)  Revision Year: 2021  Publisher: Pfizer Europe MA EEIG, Boulevard de la Plaine 17, 1050 Bruxelles, Belgium

Product name and form

Daurismo 25 mg film-coated tablets.

Daurismo 100 mg film-coated tablets.

Pharmaceutical Form

Film-coated tablet (tablet).

Daurismo 25 mg film-coated tablets: 7 mm round, yellow film-coated tablet debossed with “Pfizer” on one side and “GLS 25” on the other side.

Daurismo 100 mg film-coated tablets: 11 mm round, pale orange film-coated tablet debossed with “Pfizer” on one side and “GLS 100” on the other side.

Qualitative and quantitative composition

Daurismo 25 mg film-coated tablets

Each film-coated tablet contains glasdegib maleate equivalent to 25 mg of glasdegib.

Excipient with known effect: Each film-coated tablet contains 1.3 mg of lactose monohydrate.

Daurismo 100 mg film-coated tablets

Each film-coated tablet contains glasdegib maleate equivalent to 100 mg of glasdegib.

Excipient with known effect: Each film-coated tablet contains 5.0 mg of lactose monohydrate.

For the full list of excipients, see section 6.1.

Active Ingredient Description
Glasdegib

Glasdegib is an inhibitor of the Hedgehog (Hh) signal transduction pathway that binds to Smoothened (SMO), a transmembrane protein, leading to decreased Glioma-Associated Oncogene (GLI) transcription factor activity and downstream pathway signalling. Hh pathway signalling is required for maintaining a leukaemic stem cell (LSC) population thus, glasdegib binding to and inhibiting SMO reduces GLI1 levels in AML cells and the leukaemic initiating potential of AML cells.

List of Excipients

Tablet core:

Sodium starch glycolate
Microcrystalline cellulose (E460(i))
Calcium hydrogen phosphate (anhydrous) (E341ii)
Magnesium stearate (E470b)

Film-coating:

Lactose monohydrate
Hypromellose (E464)
Titanium dioxide (E171)
Macrogol (E1521)
Triacetin (E1518)
Iron oxide yellow (E172)
Iron oxide red (E172) (100 mg tablets only)

Pack sizes and marketing

PVC (polyvinyl chloride) blister sealed with aluminium foil containing 10 film-coated tablets, or high-density polyethylene (HDPE) bottle with polypropylene closure containing 30 or 60 film-coated tablets.

Daurismo 25 mg film-coated tablets:

One carton contains 60 film-coated tablets in 6 blisters.
One carton contains 60 film-coated tablets in an HDPE bottle.

Daurismo 100 mg film-coated tablets:

One carton contains 30 film-coated tablets in 3 blisters.
One carton contains 30 film-coated tablets in an HDPE bottle.

Not all pack sizes may be marketed.

Marketing authorization holder

Pfizer Europe MA EEIG, Boulevard de la Plaine 17, 1050 Bruxelles, Belgium

Marketing authorization dates and numbers

Daurismo 25 mg film-coated tablets:

EU/1/20/1451/001
EU/1/20/1451/002

Daurismo 100 mg film-coated tablets:

EU/1/20/1451/003
EU/1/20/1451/004

Date of first authorisation: 26 June 2020

Drugs

Drug Countries
DAURISMO Austria, Canada, Estonia, Finland, Croatia, Ireland, Lithuania, Poland, Romania, United Kingdom, United States

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.